0001140361-24-047697.txt : 20241122 0001140361-24-047697.hdr.sgml : 20241122 20241122210012 ACCESSION NUMBER: 0001140361-24-047697 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20241120 FILED AS OF DATE: 20241122 DATE AS OF CHANGE: 20241122 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Venker Eric CENTRAL INDEX KEY: 0001801917 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40782 FILM NUMBER: 241491688 MAIL ADDRESS: STREET 1: C/O ROIVANT SCIENCES, INC. STREET 2: 320 WEST 37TH STREET, 6TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10018 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Roivant Sciences Ltd. CENTRAL INDEX KEY: 0001635088 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 981173944 STATE OF INCORPORATION: D0 FISCAL YEAR END: 0331 BUSINESS ADDRESS: STREET 1: CLARENDON HOUSE, 2 CHURCH STREET CITY: HAMILTON HM11 STATE: D0 ZIP: HM11 BUSINESS PHONE: 441-295-5950 MAIL ADDRESS: STREET 1: CLARENDON HOUSE STREET 2: 2 CHURCH STREET CITY: HAMILTON STATE: D0 ZIP: HM11 4 1 form4.xml FORM 4 X0508 4 2024-11-20 0001635088 Roivant Sciences Ltd. ROIV 0001801917 Venker Eric C/O ROIVANT SCIENCES LTD. 7TH FLOOR, 50 BROADWAY LONDON X0 SW1H 0DB UNITED KINGDOM true President & COO true Common Shares 2024-11-20 4 F 0 10945 11.49 D 606525 D Common Shares 2024-11-20 4 M 0 100000 3.85 A 706525 D Common Shares 2024-11-20 4 S 0 100000 11.32 D 606525 D Stock Option (Right to Buy) 3.85 2024-11-20 4 M 0 100000 0 D 2032-04-19 Common Stock 100000 12326234 D Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs. The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on June 25, 2024. Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation). By: /s/ Jo Chen, as Attorney-in-Fact for Eric Venker 2024-11-22